Falling short: Inadequate target attainment in guideline-based therapy of nontuberculous mycobacterial disease

In the world of infectious disease, some bacteria are notorious for their ability to hide and resist treatment, but a specific group known as nontuberculous mycobacteria has become an increasingly difficult problem for doctors. These are opportunistic pathogens, meaning they often wait for a person's immune system to be weakened before causing infection, and they are appearing in growing numbers of patients. While standard treatments for these infections involve taking a combination of several antibiotics for years, the success rate remains frustratingly low. The core of the difficulty lies in a mismatch between the drugs we have and the bugs they are meant to kill. The antibiotics currently used were originally designed for other bacteria, and when repurposed for these stubborn mycobacteria, they often lack the necessary strength or fail to reach high enough levels inside the body to do their job effectively.

A new study set out to measure exactly how well these standard treatments are performing by looking at the relationship between the amount of drug in the body and the amount needed to stop the bacteria from growing. Researchers used existing data on how drugs move through human bodies and combined it with information on how resistant different bacteria are to these medicines. They calculated the likelihood that a patient taking a standard dose would receive enough of the drug to be effective, a concept known as target attainment. To provide a clear benchmark, they compared these results against treatments for tuberculosis, a related disease where cure rates are excellent, to see where the current nontuberculous mycobacterial therapies fall short.

The analysis revealed a stark reality: for most patients with nontuberculous mycobacterial infections, the standard drug regimens are failing to reach the necessary levels to ensure a cure. The study found that the probability of achieving the required drug exposure is generally low across the board, and these low numbers align closely with the poor clinical outcomes doctors see in practice. However, the data did highlight specific exceptions where the treatment logic holds up. For instance, the study confirmed that macrolide antibiotics are effective against certain types of these bacteria because the bacteria that survive these drugs usually have genetic changes that make them resistant, suggesting the drug is doing its job on the susceptible ones. Similarly, rifampicin showed strong results for a specific species called M. kansasii.

The research also pointed toward potential improvements for the future. The simulations suggested that bedaquiline, a drug often used for tuberculosis, could be a promising option for treating difficult cases of M. abscessus and the M. avium complex. Another drug, clofazimine, also showed favorable results for the latter group. Furthermore, the study indicated that omadacycline might work better than the currently used tigecycline for patients with M. abscessus and could be useful for the M. avium complex as well. These findings do not represent a sudden cure, but rather a quantitative map of where current therapies are falling short and where new combinations might succeed. By understanding these probabilities, medical experts can begin to refine treatment guidelines and design better clinical trials, moving away from guesswork toward a strategy grounded in how the drugs actually behave inside the human body.